transplanted in remission or relapse ( p < 0.05). Chronic GVHD came earlier in the group that started photochemotherapy after 1 week of acute GHVD, but chronic GVHD did not increase the GVL. Conclusion: The timing of photochemotherapy after cutaneous acute GVHD may direct the GVL and predict long-term leukemia-free survival.
bone marrow transplantation may to a lesser extent transfer a subset of NK cells, mostly found in the liver [10, 11] , which may develop an adaptive immunity after cutaneous antigen sensitization [12, 13] . Therefore, one key to long-term leukemia-free survival (LFS) may be to protect the patient from the acute GVHD of the skin while preserving a putative concomitant adaptive part of the GVL.
In GVHD of the skin, regulatory T cells (T reg cells) and the histamine-producing mast cells are both present and may interplay [14, 15] . Therapy with T reg cells has been suggested as one way to separate GVL from GVHD [16] . Recently a modulation of the T reg population by a combination of histamine dihydrochloride and IL-2 has been suggested to be a mediator of a prolonged remission of acute myeloid leukemia [17] . Repeated low-dose topical photochemotherapy increases the T reg cells in the circulation and in the spleen of mice with skin inflammation [18] , and an increase in T reg cells has been confirmed in psoriatic patients after bath photochemotherapy [19] . In addition, photochemotherapy modulates the human cutaneous mast cell wheal responsiveness while the immediate flare response to histamine is increased [20] . In allergic patients, photochemotherapy suppresses the delayed-type hypersensitivity reaction (DTH) independent of the erythematous reaction of the skin, which is different from ultraviolet light type B where the erythematous reaction correlates with the suppression, whereas both therapies decrease the antigen-presenting Langerhans dendritic cell population in the treated area of the skin [21] . A decrease in DTH of the skin after photochemotherapy was found early in psoriatic patients [22] . Animal models of acute GVHD show elements of a DTH and subcutaneous provocation with alloantigen in naïve hosts created antigen-specific responses [23, 24] . In mice, photochemotherapy may suppress DTH in the skin distant from the area treated, and this distant effect may be blocked by ketanserin, an unspecific serotonin inhibitor, which blocks the migration of not only mast cells [25] , but also the dendritic cell migration 47 and T-cell priming [26] . Yet, the systemic effect of photochemotherapy remains disputed, and the mediation thereof is not clearly chartered, but we have found that photochemotherapy of the skin may suppress acute GVHD of the internal organs in patients who had received total body irradiation (TBI) [27] . The experimental acute-GVHD reaction and the DTH reaction may both elicit effector cells within a week [28] , and a week is what is needed to induce GVL in animal models [29, 30] . Photochemotherapy is used world-wide based on the hypothesis that the selective treatment of the skin will not affect the systemic immunity. In allogeneic stem cell transplantation, the search for selective immunosuppression of GVHD is the search for "the holy grail" -to be able to heal the life-threatening GVHD while preserving the life-saving GVL. To further evaluate the systemic immunomodulatory effects of photochemotherapy of acute GVHD of the skin, we decided to study the effects on GVL of acute leukemia when photochemotherapy was started during the first week of clinical acute GVHD of the skin, compared to a start of photochemotherapy after the first week of acute GVHD.
Material and Methods
For further details, see the online supplementary material (for all online suppl. material, see www.karger.com/10.1159/000484138) [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] ( Fig. 1 ; Tables 1-3 ).
Results

Patient Characteristics and Acute GVHD
Response of Acute GVHD to Photochemotherapy Regardless of whether the photochemotherapy was started during the first week of cutaneous acute GVHD or not, the number of treatments and the accumulated dose of photochemotherapy were comparable ( Table 4 ). In the group of patients who started photochemotherapy within the first week of acute GVHD of the skin, 77% (10 of 13) had complete remission (CR) of acute GVHD, 85% (11 of 13) had CR + partial remission (PR), 1 no response (NR) and 1 progressed. Two patients received methotrexate in addition to photochemotherapy, 1 was treated with 1 In vitro T-cell depleted grafts or in vivo T-cell depletion after conditioning with antithymocyte globulin (ATG); ns, not significant. methotrexate and cyclosporine as GVHD prophylaxis and 1 with prednisolone and cyclosporine as GVHD prophylaxis. Among the patients who started photochemotherapy after more than 7 days of acute GVHD of the skin, 76% (26 of 34) had CR; 88% (30 of 34) had CR + PR; 3 patients had NR, and 3 progressed. Seven patients received methotrexate concomitantly with photochemotherapy, 6 methotrexate and cyclosporine as acute-GVHD prophylaxis while 1 received a T-cell-depleted graft. One patient required additional treatment beyond methotrexate; after high-dose prednisone and the start of photochemotherapy on day 18 of acute GVHD, this patient additionally received extracorporeal photochemotherapy, infliximab, daclizumab, and mesenchymal stem cells.
GVL and Survival after Photochemotherapy GVL was present in 25 out of 47 patients whereas 21 patients had leukemia relapse and 1 patient was administered a donor lymphocyte infusion (DLI) to prevent a minimal residual disease from turning into fulminant relapse. The primary predictor, time to treatment by photochemotherapy, was the multivariate predictor of GVL ( Fig. 2 ; Table 5 ). A higher relapse risk had 2 predictors, a shorter time to treatment with photochemotherapy and a lower stage of skin disease at the start of photochemo- ( Fig. 3 a, b ; Table 5 ). Survival with preserved GVL and LFS was predicted by a longer time to photochemotherapy ( Fig. 4 a, b) , but not of skin disease stage at the start of photochemotherapy ( Fig. 4 c; Table 6 ). Time from acute GVHD to photochemotherapy was a multivariate predictor for GVL both as a binary variable and as a continuous variable ( Table 7 ). The 10-year nonrelapse mortality, GVL, LFS, and overall survival divided by start of photochemotherapy within 1 week versus after 1 week of acute GVHD were 35 versus 38%, 18 versus 54%, 8 versus 37%, and 23 versus 38%, respectively. Start of photochemotherapy within 1 week versus after 1 week of clinical acute GVHD had an impact on GVL irrespective of whether the patients were transplanted in remission ( n = 36; 0 vs. 51%; p = 0.022) or relapse ( n = 11; 0 vs. 64%; p = 0.040). The difference in 5,000-day survival with preserved GVL was 0 versus 34% for patients transplanted in remission and 0 versus 50% ( p = 0.048) for patients transplanted in relapse. The group who received photochemotherapy within a week from acute GVHD developed chronic GVHD later: on median day 311 (min.-max. 217-555, n = 6) compared with day 181 (58-655, n = 16, p < 0.001).
An exploratory analysis showed that the group with 10-year survival with preserved GVL ( n = 13) started photochemotherapy on day 18 (interquartile range 13-38, min.-max. , while the patients with less favorable outcome ( n = 34) started photochemotherapy on day 14 (1-22, p = 0.036; Fig. 5 a, b) .
Discussion
We indicate that photochemotherapy aimed at controlling cutaneous acute GVHD may de facto regulate the GVL effect in acute leukemia dependent on the time between the acute-GVHD diagnosis and the start of photochemotherapy. The effect was persistent regardless of whether the patients were transplanted in remission or relapse of the acute leukemia. Early photochemotherapy abrogates the GVL, but photochemotherapy started after 1 week of acute GVHD may help to stabilize the GVL effect also in patients with acute myeloid leukemia or acute lymphoblastic leukemia that cannot be brought into remission before transplantation.
In this retrospective observational study as in all nonrandomized retrospective studies, the internal validity is at hazard, here by unintended selection bias in the situation when the clinical decision to initiate photochemotherapy was made. To balance bias we used objective pre- 309 dictors and prospective outcomes, i.e. time to treatment after acute GVHD, survival, and relapse or DLI to prevent from relapse. We used strict eligibility and patients who received photochemotherapy for acute GVHD elicited by an additional booster dose of donor stem cells or T cells after the transplantation were excluded which allowed us to specify the GVL effect to be limited not only by relapse, but also by DLI for minimal residual disease and to be limited by graft failure as a competing event in the analysis. The choice of Cox proportional hazard ratio for the multivariate analysis may be disputed, but, as the number of events per variable in the final solution was above 20 and the primary predictor proved to be the only significant predictor in forward and backward regression, the model was stable [45] . Patients who started the photochemotherapy after 1 week or more of acute GVHD were more frequently treated with steroids at the start of photochemotherapy but we assign limited importance to the confounding effect of the glucocorticoid administration as steroid-resistant acute GVHD at the start of photochemotherapy was not a uni-or multivariate predictor of GVL. With caution to the low number of patients, we suggest that photochemotherapy started after 1 week may spare the GVL effect and may be coupled to a substantial GVL in the patients who were transplanted without remission, as the long-term LFS for acute leukemia transplanted in relapse for acute myeloid leukemia and acute lymphoblastic leukemia are 50% (67 and 33%), respectively, compared to the previously published LFS of less than 20% [46, 47] . Our finding that a skin therapy may also regulate systemic tumor immunity in humans dependent on the time between the start of an immune reaction of the skin to the start of the skin therapy is of general importance. We confirm the findings of Truitt et al. [48] , who in 2 experiments with a major histocompatibility complexmismatched murine model of bone marrow transplantation demonstrated that photochemotherapy of a part of the cells ex vivo may limit GVHD but also, at a narrow therapeutic dose interval of the psoralen (S59) and UVA, may preserve the antileukemic effect.
Furthermore, our results underscore that it may be possible to develop protocols which include photochemotherapy that induces long-term disease-free survival for high-risk leukemia. So far, in humans, Schlaak et al. [49] demonstrated the benefits of photochemotherapy and bexarotene to modulate the effects of DLIs to induce long-term relapse in a case of advanced-stage cutaneous T-cell lymphoma.
During the period from 1990 to 2002, several reports of the effect of photochemotherapy on cutaneous GVHD were published but none evaluated a systemic effect, nor effects on systemic tumor immunity or long-term survival without recurrent malignant disease [50] [51] [52] [53] . The last patient in this report was treated in 2002, and by exploratory analysis we identified that the group of patients with 10-year survival and a preserved GVL started photochemotherapy on day 18 (8-52) of acute GVHD of the skin. This time interval between GVL and GVHD can be compared to the time difference found by Hari et al. [54] On the row below each variable or predictor shown in the left column are the categories and the number of patients (in parentheses) in each category. The multivariate predictors are shown in bold. * p < 0.05, ** p < 0.01. The events per variable were 34, 33, and 32 for survival with preserved GVL, LFS and OS, respectively. In the analysis of chronic GVHD only patients who survived without relapse or DLI for 100 days were included, the events per variable were 26 for survival with preserved GVL, 25 for LFS, and 24 for OS. IBMTR, Center for International Blood and Marrow Transplant Research; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; ATG, antithymocyte globulin. 311 where 14 days was estimated to be the median difference between GVL and GVHD after DLI and the time interval without GVHD prophylaxis in the study of high-risk leukemia of Fassas et al. [55] . They omitted the graft-versushost prophylaxis after a TBI-based myeloablative conditioning with addition of antithymocyte antibodies which resulted in a GVHD with 100% skin involvement and a hyperacute onset (median 9 days, range 8-14 days) followed by a long-term disease-free survival of a median 14 months (5-27) in 45% of the cases. Photochemotherapy is known to suppress adaptive immunology [22, 56] . The fact that the start of photochemotherapy in the group where GVL was abrogated was on median day 1 and that the effect was sustained during a long-term follow-up suggests that GVL in humans may be strengthened by antigen sensitization, effector cell generation and immunological memory primed during the first week of the acute GVHD of the skin. Considering the relatively high rate of preserved GVL in high-risk leukemia we present after a delayed treatment of photochemotherapy, compared to an early photochemotherapy, in general, the present study indicates that photochemotherapy has a systemic immunomodulatory effect in humans. The acute GVHD in this cohort with acute-GVHD skin involvement was limited to an index B (median) with no stage 4 organ disease and a low presence of liver and gastrointestinal disease. An increased skin disease stage predicted a decreased relapse risk in the multivariate analysis and indicates that photochemotherapy may wait until an appropriate time interval to optimize GVL, even if the skin disease progresses. This is supported by our previous report of patients with acute GVHD both in the skin and viscera, where the time to treatment by photochemotherapy after acute-GVHD diagnosis was a median 21 days (interquartile range 12-28, min.-max. 1-43 days), in the group of patients who reached CR of acute GVHD of the liver and the gastrointestinal channel, a CR that was associated with conditioning with TBI and longterm survival [27] . In the present report, no adverse syn- ergy of TBI on tumor immunity was found. All patients with a conditioning of busulfan and cyclophosphamide responded in the skin, and so did the majority who received TBI and cyclophosphamide. The magnitude of our result should be interpreted with caution outside the field of allogeneic transplantation. The effect on patient immunity by the transplantation conditioning regimen, the grafted cells and the immunosuppressive GVHD prophylaxis may be a prerequisite for the time-dependent regulatory effects on tumor immunity of photochemotherapy indicated in this work. However, in hematology reduced-intensity conditioning, which has decreased the toxicity of transplantation and increased the possibilities to transplant more fragile patients, is dependent on the GVL why the timing of photochemotherapy after reduced-intensity conditioning may be most vital. Further, in chronic myeloid leukemia, GVL after DLI has been suggested to be temporally separated from acute GVHD. Therefore retrospective studies of photochemotherapy evaluating the effect on GVL after GVHD in acute and chronic leukemia, with or without reduced-intensity conditioning, would be of interest. To conclude, the observation that photochemotherapy may have an effect on systemic tumor immunity in transplanted patients is of clinical importance and warrants further studies, if possible with adequate tissue and blood sampling to further elucidate the systemic immunomodulatory effects of photochemotherapy.
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Key Message
Delayed photochemotherapy to control graft-versus-host disease may improve the graft-versus-leukemia effect and is associated with long-term disease-free survival.
